article thumbnail

First patient receives new engineered mRNA epigenetic

European Pharmaceutical Review

revealed the first patient to be dosed with OTX-2002, the first programmable mRNA therapeutic for c-Myc (MYC) oncogene overexpression, which targets cancer cells while sparing healthy cells. OTX-2002 is delivered via lipid nanoparticles (LNPs) and controls the expression of specific genes using epigenetics, a new era of medicine. .

article thumbnail

Personalizing the Cancer Patient Journey

Pharma Marketing Network

The patient care team supplies an abundance of information, although sifting through brochures and online resources can be daunting for the patient and their caregiver. 1 The marketer’s goal is to design easy-to-follow patient guidelines while conforming to med-legal language. Meeting Patients Where They Are.

Patients 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Lung cancer deaths decline but.

World of DTC Marketing

The mortality rate from lung cancer has dropped in recent decades—by 56% in men from 1990 to 2019 and by 32% in women from 2002 to 2019. The mortality rate from lung cancer has dropped in recent decades—by 56% in men from 1990 to 2019 and by 32% in women from 2002 to 2019. Click to Tweet. It’s both good and bad news.

Insurance 271
article thumbnail

Synapse Biomedical Wins New Approval for Diaphragm Pacing System to Free Patients from Ventilators

Legacy MEDSearch

announced today that the FDA has granted premarket approval (PMA) of the NeuRx ® Diaphragm Pacing System (NeuRx DPS ® ) for use in patients with spinal cord injuries who rely on mechanical ventilation. It is intended for use in patients with stable SCI with stimulatable diaphragms, but who lack control of their diaphragms.

article thumbnail

Adalimumab biosimilars shaping market, research states

European Pharmaceutical Review

billion in 2022, a product that was launched in 2002. The Soliris (eculizumab) biosimilar is indicated as a treatment for patients with the rare haematology disorder paroxysmal nocturnal haemoglobinuria (PNH). There are at present, nine US Food and Drug Administration (FDA)-approved agents, GlobalData stated.

article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

When patients experience intense emotion, either positive or negative, they are rendered unconscious. Sodium oxybate — which in the late 1980s was marketed to bodybuilders and then became known as GHB and criminally used as a date rape drug — has been sold under the brand name Xyrem after gaining FDA approval in 2002.

article thumbnail

mRNA non-vaccine therapeutics to generate $2 billion by 2028

European Pharmaceutical Review

GlobalData stated that if development is successful for Ultragenyx’s OTX-2002 , which has potential to be the first programmable epigenetic medicine, it could generate $1.6 billion during 2028. Challenges facing mRNA therapeutics.